Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack

Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When... Key PointsQuestionIs the preventive migraine treatment intravenous eptinezumab effective when initiated during a migraine attack? FindingsThis randomized clinical trial included 480 patients eligible for preventive migraine therapy who had a moderate to severe migraine attack. Treatment with eptinezumab vs placebo during a migraine attack resulted in median time to headache pain freedom of 4 hours vs 9 hours and median time to absence of most bothersome symptom of 2 hours vs 3 hours, respectively; both comparisons were statistically significant. MeaningAmong patients eligible for preventive migraine therapy, treatment with intravenous eptinezumab vs placebo during an active moderate to severe migraine attack shortened time to headache and migraine symptom freedom. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack

Loading next page...
 
/lp/american-medical-association/effects-of-intravenous-eptinezumab-vs-placebo-on-headache-pain-and-TrX16Mzonl
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.7665
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionIs the preventive migraine treatment intravenous eptinezumab effective when initiated during a migraine attack? FindingsThis randomized clinical trial included 480 patients eligible for preventive migraine therapy who had a moderate to severe migraine attack. Treatment with eptinezumab vs placebo during a migraine attack resulted in median time to headache pain freedom of 4 hours vs 9 hours and median time to absence of most bothersome symptom of 2 hours vs 3 hours, respectively; both comparisons were statistically significant. MeaningAmong patients eligible for preventive migraine therapy, treatment with intravenous eptinezumab vs placebo during an active moderate to severe migraine attack shortened time to headache and migraine symptom freedom.

Journal

JAMAAmerican Medical Association

Published: Jun 15, 2021

References